Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New appointments at Aragon Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Aragon Pharmaceuticals (US), privately held small-molecule drug discovery company identifying medicines for the treatment of hormonally driven cancers, has appointed Dr Richard Heyman chief executive officer, and has elected Dr Ronald Evans and Dr David Mangelsdorf to its scientific advisory board. Dr Heyman has 20 years' drug discovery experience in the biotech sector, having most recently co-founded Aragon in 2009. Before that, he was chief scientific officer at Kalypsys, where he conducted drug discovery in therapeutic areas including metabolic diseases, pain and inflammation. Dr Evans is professor in the gene expression laboratory and March of Dimes Chair in molecular and developmental biology at the Salk Institute for Biological Studies in La Jolla, California, while Dr Mangelsdorf has been at the University of Texas Southwestern Medical Center in Dallas, where he has been professor and chair of the department of pharmacology, since 1993.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC009788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel